- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07940387
IV Lidocaine in Ortho Trauma Patients
The Efficacy of Perioperative Intravenous Lidocaine as an Opioid Sparing Adjunct for Patients Undergoing Lower Extremity Orthopedic Trauma Surgery
In this research study, we will be evaluating whether an anesthesia provider using the method of intravenous lidocaine infusion during the perioperative and immediate postoperative period can provide equal short-term pain control and decrease postoperative opioid consumption compared to traditional opioid utilization. We will also evaluate the effects of intravenous lidocaine on inflammatory mediators such as interleukins and cytokines through timed lab draws. The study hypothesis is that intravenous lidocaine will provide similar pain relief and decrease the amount of post operative opioids used, as well as decrease the amount of inflammatory mediators present compared to conventional post-operative treatment utilizing solely opioids.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Recrutamento
- Detroit Receiving Hospital
-
Contato:
- Jessica Phillips, PhD, CRNA
- Número de telefone: 313-577-9239
- E-mail: fy9015@wayne.edu
-
Contato:
- Mary Golinski, PhD, CRNA
- Número de telefone: 248 364 8776
- E-mail: golinski@oakland.edu
-
Investigador principal:
- Jessica Phillips, PhD, CRNA
-
Investigador principal:
- Mary Golinski, PhD, CRNA
-
Investigador principal:
- Wael Saasouh, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- ASA physical status I-III, males and females >18 years of age and < 85 years of age, scheduled for repair of lower extremity (orthopedic) fracture/s of a single extremity. The type of injury will be documented and categorized- as applicable- in demographic data. The type of fracture will be extracted from the electronic surgical/operative report i.e. preoperative and postoperative diagnosis.
Exclusion Criteria:
- Contraindication to lidocaine including allergy, substantial hepatic impairment (alanine aminotransferase greater than 120 IU/L or aspartate aminotransferase > 80 IU/L), substantial renal impairment (serum creatinine >2 mg/dL), current history of narcotic abuse, cognitive impairment (any patients who are alert and oriented x2 or less; for example, 0-2), cardiac ejection fraction less than 20% by documented cardiac consultation and evaluation, history of seizure disorders, and patients with documented sensory impairments such as neuropathies, fibromyalgia, and diabetes mellitus with concomitant neuropathies (because these sensory impairments may confound postoperative measurements of pain). Cardiac Ejection Fraction less than 20% further explained: Patients who are admitted to the hospital and scheduled for surgery that are deemed high cardiac risk (by history and physical and/or per patient) routinely have echocardiograms per standard of care, and if necessary further cardiac consultations and 'work ups' are performed at Detroit Receiving Hospital. With the thorough history and physical that is required, the results will be available prior to surgery and anesthesia. If a patient has demonstrated 'no cardiac risk factors' after a complete history and physical examination, they will be assumed to have a normal ejection fraction. Pregnant women will also be excluded as there have been no controlled studies in humans investigating the potential effects of intravenous lidocaine during pregnancy. All patients undergo a serum or urine HCG test prior to surgery, and these will be evaluated by the researchers.
Patients under the age of 18 will be excluded due to recent studies finding adverse reactions, although mild, appear to be common in children. Oxygen saturation of <95% on room air will be excluded per the lidocaine package insert. Weight of 150 kg (330 lbs) will be excluded per the lidocaine package insert.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Control Group - Saline Infusion
Saline bolus and infusion |
Saline infusion |
|
Experimental: Intervention - IV Lidocaine Group
Lidocaine bolus and infusion |
A Lidocaine (LID) bolus 2mg/kg followed by an infusion rate of 2 mg/kg/hr. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Morphine equivalents
Prazo: from enrollment to 14 days postoperative
|
Amount of opioids in morphine milligram equivalents (MME) used in 2 weeks/14 days postoperative period |
from enrollment to 14 days postoperative
|
|
Interleukin 6 (IL-6)
Prazo: 1, 6, 24 and 48 hours postoperative
|
Interleukin 6 (IL-6) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL |
1, 6, 24 and 48 hours postoperative
|
|
Interleukin 8 (IL-8)
Prazo: 1, 6, 24 and 48 hours postoperative
|
Interleukin 8 (IL-8) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL |
1, 6, 24 and 48 hours postoperative
|
|
Complement C3a
Prazo: 1, 6, 24 and 48 hours postoperative
|
Complement C3a present in serum plasma at 1, 6, 24 and 48 hours postoperative in ng/mL |
1, 6, 24 and 48 hours postoperative
|
|
Visual Analogue Pain Score
Prazo: Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.
|
Visual Analogue Pain Score with 0 = no pain and 10 = worst pain ever. |
Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Quantitative Sensory Testing
Prazo: Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)
|
Mechanical and thermal pain thresholds will be measured adjacent to the incision site to measure hyperalgesia |
Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRB 24-11-7305
- 2025-G-5 (Número de outro subsídio/financiamento: AANA Foundation)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Any information containing patient information or protected health information (PHI) such as master list documents containing patient names and medical record numbers will be stored securely in a locked office inside a locked filing cabinet at the DMC site. All other data will use a subject number assigned and remove all 18 types of PHI information De-identified and be hard copies (paper records) will also be stored securely in a locked office inside a locked filing cabinet. DMC collected data will be saved on the DMC secure server in the Citrix platform. Study data will only be accessible to investigators involved in the study. Statistical analysis will be performed on de-identified encrypted digital data.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .